Run-up to participation in ATACH II in Japan

Article Sidebar

PDF https://doi.org/10.5281/zenodo.10349303
Published: Nov 12, 2023

Main Article Content

K Toyoda
S Sato
M Koga
H Yamamoto
J Nakagawara
E Furui
Y Shiokawa
Y Hasegawa
S Okuda
N Sakai
K Kimura
Y Okada
S Yoshimura
H Hoshino
Y Uesaka
T Nakashima
Y Itoh
T Ueda
T Nishi
J Gotoh
K Nagatsuka
S Arihiro
T Yamaguchi
K Minematsu

Abstract

Intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality in Japan. Seventeen Japanese
institutions are participating in the Antihypertensive Treatment for Acute Cerebral Hemorrhage (ATACH)
II Trial (ClinicalTrials.gov no. NCT01176565; UMIN 000006526). This phase III trial is designed to determine the therapeutic benefit of early intensive systolic blood pressure (BP) lowering for acute hypertension
in ICH patients. This report explains the long run-up to reach the start of patient registration in ATACH II
in Japan, including our preliminary study, a nationwide survey on antihypertensive treatment for acute ICH
patients, a multicenter study for hyperacute BP lowering (the SAMURAI-ICH study), revision of the official Japanese label for intravenous nicardipine, and construction of the infrastructure for the trial.

Downloads

Download data is not yet available.

Article Details

How to Cite
K Toyoda, S Sato, M Koga, H Yamamoto, J Nakagawara, E Furui, Y Shiokawa, Y Hasegawa, S Okuda, N Sakai, K Kimura, Y Okada, S Yoshimura, H Hoshino, Y Uesaka, T Nakashima, Y Itoh, T Ueda, T Nishi, J Gotoh, K Nagatsuka, S Arihiro, T Yamaguchi, & K Minematsu. (2023). Run-up to participation in ATACH II in Japan. Journal of Vascular and Interventional Neurology, 5(1.5). Retrieved from https://ojs.jvin.org/index.php/jvin/article/view/331
Issue
Vol. 5 No. 1.5 (2012): August
Section
Original Research Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.